Abarceo Pharma
  • About
  • Team
    • Management
    • Board
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page
Abarceo attended ATTD

Abarceo attended ATTD

by SD-AbarceoPharma | Mar 29, 2026 | Diabetes, Events, News & Press releases

11–14 March Abarceo attended the ATTD in Barcelona. Abarceo promoted its development to become the first company to provide the diabetes community with a drug that will adress major hallmarks of diabetes. That is including restoration of patients own insulin...

Recent Posts

  • RESI Europe 2026
  • Abarceo attended ATTD
  • World Diabetes Day
  • NLS Days 2025
  • Abarceo attended Biostock’s event in Stockholm

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2026 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy